University of Tennessee

tennessee.edu

Total trials

176

Active

32

Phase 3

9

Total enrollment

78,306

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Marcaine hydrochloride without epinephrine 0.5%1
Oxycodone1
Hydromorphone1
Cefiderocol1
Ketamine1
0.9% NaCl1
umeclidinium 62.5 µg and vilanterol 25 µg1
Revefenacin 175 µg, Formoterol 20 µg1
Bupivicaine intervention arm1
Zinc Sulfate1
124I-evuzamitide1
dexamethasone2
Ropivacaine 0.5% Injectable Solution1

Next readouts

  • 2025-07-01
  • 2025-12
  • 2025-12
  • 2025-12-01
  • 2026-02
  • 2027-02-28
  • 2027-03
  • 2027-12-31
  • 2028-05

Top conditions

  • Obesity8
  • Preeclampsia6
  • Endocrine Disorders of Female Reproductive System3
  • Opioid Use3
  • Weight Loss3
  • Pregnancy3
  • Pain, Postoperative3
  • Pain3

Frequently asked questions about University of Tennessee

How many clinical trials does University of Tennessee have on ClinicalTrials.gov?
University of Tennessee is listed as the lead sponsor on 176 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Tennessee's trials are in Phase 3?
9 of University of Tennessee's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does University of Tennessee focus on?
University of Tennessee's most-studied conditions on ClinicalTrials.gov are Obesity, Preeclampsia, Endocrine Disorders of Female Reproductive System, Opioid Use, Weight Loss.
When are University of Tennessee's next clinical trial readouts?
University of Tennessee has 9 upcoming primary-completion readouts tracked here; the soonest is “Enteral Zinc Supplementation in Very Low Birth Weight Infants”, expected around 2025-07-01.